Clinical Trials Logo
  1. Home
  2. Solid Tumor, Unspecified, Adult
  3. NCT04976803

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein — ATM  

Solid Tumor, Unspecified, Adult Clinical Trial

Official title:
A Tissue Collection Study to Explore the Correlation Between ATM Genetic Alterations by Next-Generation Sequencing and ATM Loss-of-Protein Via IHC (ATR-ID Study)

Clinical Trial Summary

This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Clinical Trial Description

The purpose of this study is to address whether ATM genomic aberrations could be used to enrich for patients with ATM LoP. Screening of unselected patient populations for ATM protein loss is likely to a lead to high failure rate by IHC testing, as the prevalence of this is expected to be low. This study could allow for identification of the types of ATM aberrations that lead to ATM LoP, and thus significantly decrease IHC failure rate by pre-selecting patients harboring such aberrations. In this study the investigator will be collecting archival tumor tissue or fresh tissue which will be assessed for ATM LoP and compared to NGS data. Additionally, patients whose tumors exhibit ATM LoP within this study could potentially enroll onto the treatment study REFMAL 721/ART0380C001. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04976803
Study type Observational
Source Artios Pharma Ltd
Contact
Status Completed
Phase
Start date May 28, 2021
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03628677 - A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Phase 1
Recruiting NCT05723640 - The Safety and Dosimetry Study of 177Lu-LNC1004 Injection Phase 1
Recruiting NCT04932525 - Gustave Roussy Cancer Profiling Phase 1
Recruiting NCT04643418 - Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04443088 - An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04942717 - Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
Recruiting NCT04169321 - Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors Phase 1
Recruiting NCT05695638 - Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Completed NCT03318445 - Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Phase 1
Recruiting NCT04537936 - Psychotherapy Intervention for Latinos With Adv Cancer N/A
Completed NCT04252339 - RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04577963 - A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06136065 - 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors Phase 2
Recruiting NCT04015609 - Psychotherapy Intervention for Latinos With Advanced Cancer N/A
Available NCT04100694 - Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor